RheoSwitch Therapeutic System receptor (RTS receptor)

The **RheoSwitch Therapeutic System receptor** is not a native biological receptor but a synthetic chimeric receptor complex used for externally controlled gene expression in gene and cell therapy platforms. It comprises two engineered fusion proteins—one containing a modified ligand-binding domain derived from insect ecdysone receptor fused to a DNA-binding domain, and another containing a co-activator (e.g., VP16-RXR, Gal4-EcR)[2][5][7]. The system is silent ("OFF") until an orally available synthetic ligand, such as veledimex, is administered; this ligand binds the receptor complex, inducing its dimerization and recruitment to an inducible promoter, thus activating transcription of a transgene (e.g., IL-12 in cancer therapy)[2][4][5][7]. The system allows for tunable, reversible, and tissue-specific gene expression, mainly used in controlled cancer immunotherapy (such as Ad-RTS-hIL-12), although any gene of interest can be placed under its control. Main safety concerns relate to the toxicity of the transgene product rather than the receptor itself, with dosing adjustable to mitigate risks[3][4][5]. **Note regarding is_incorrect:** "RheoSwitch Therapeutic System receptor" is not a canonical, well-recognized name for a molecular target but refers to a synthetic gene switch composed of engineered protein components rather than a single defined receptor. It is not found as a standard entry in major molecular target or gene/protein databases, and the name in this context may be misleading or overly broad. The closest related entities are the components of the RTS complex: chimeric ecdysone receptor and RXR fusion proteins[2][5][7].

Other names

RheoSwitchRheoSwitch gene switchRheoSwitch Therapeutic SystemRTS

Ligand-induced formation of an active transcription factor complex that binds to a synthetic inducible promoter, activating transcription of transgenes placed under its control[2][5][7].